<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nitrates in the management of acute coronary syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nitrates in the management of acute coronary syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nitrates in the management of acute coronary syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Guy S Reeder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sublingual, intravenous, and oral nitrate preparations are used in the management of acute coronary syndromes. Most of the published data come from patients with myocardial infarction (MI), but the conclusions would apply to patients with unstable angina.</p><p>The role of nitrates in the management of acute coronary syndrome, which includes ST-elevation and non-ST elevation MI, as well as unstable angina, will be reviewed here. The role of nitrate therapy in patients in the emergency department suspected of having chest pain due to myocardial ischemia and the overall management of the patient with an MI are discussed separately. (See  <a class="medical medical_review" href="/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department", section on 'Immediate emergency department interventions'</a> and  <a class="medical medical_review" href="/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a>.)</p><p class="headingAnchor" id="H46117994"><span class="h1">MECHANISMS OF ACTION</span><span class="headingEndMark"> — </span>Potential mechanisms by which nitrates can relieve ischemic pain include:</p><p class="bulletIndent1"><span class="glyph">●</span>Dilatation of large coronary arteries and arterioles (&gt;100 millimicrons [nanometers] in diameter), which may lead to increased perfusion of ischemic zones.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dilatation of the venous system with decreased preload, reduction in ventricular volume, and a fall in pulmonary capillary wedge pressure. This effect is useful in patients with pulmonary congestion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic arterial dilatation, which decreases afterload, also occurs but to a lesser degree. These changes lower wall stress and oxygen consumption and can reverse a restrictive filling pattern [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Termination of an episode of variant angina. (See  <a class="medical medical_review" href="/d/html/1481.html" rel="external">"Vasospastic angina"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enhanced collateral blood flow.</p><p></p><p>Nitrates produce these effects by entering vascular smooth muscle cells and combining with sulfhydryl groups to form nitric oxide and eventually S-nitrosothiols  (<a class="graphic graphic_figure graphicRef50622" href="/d/graphic/50622.html" rel="external">figure 1</a>). The nitroso-thiols stimulate guanylate cyclase to produce cyclic guanosine monophosphate (cGMP), which causes smooth muscle relaxation by decreasing intracellular calcium levels. (See  <a class="medical medical_review" href="/d/html/1549.html" rel="external">"Nitrates in the management of chronic coronary syndrome", section on 'Mechanism of action'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SIDE EFFECTS AND CAUTION</span><span class="headingEndMark"> — </span>The primary adverse effects induced by nitrate therapy include hypotension (especially in patients with ventricular ischemia or hypovolemia), headache, and tachycardia. Hypovolemia or nitrate-induced hypotension respond promptly to volume replacement. Despite presumed correction of preload by the infusion of <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, the antiischemic effect of <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> persists.</p><p>Prolonged infusion of high dose <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> may lead to the development both of methemoglobinemia (which can be treated with intravenous <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a>) and of heparin resistance. In addition, commercial preparations of intravenous nitroglycerin contain alcohol (0.01 to 0.14 mL/mg of nitroglycerin). Thus, a substantial alcohol load may be delivered to the patient. (See  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia"</a>.)</p><p>Nitrates in all forms should be <strong>avoided</strong> in patients with one or more of the following [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Systolic blood pressure less than 90 mmHg or ≥30 mmHg below baseline. Nitrates may induce symptomatic hypotension and can lead to hemodynamic decompensation in the setting of cardiac ischemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Marked bradycardia (heart rate less than 50 beats per minute) or tachycardia (heart rate greater than 100 beats per minute). In this setting nitrates may cause hemodynamic decompensation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Known or suspected right ventricular infarction. Nitrates should be avoided because of the increased risk of inducing hypotension. (See  <a class="medical medical_review" href="/d/html/75.html" rel="external">"Right ventricular myocardial infarction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have taken a phosphodiesterase inhibitor for erectile dysfunction within the last 24 hours (or perhaps as long as 48 hours with <a class="drug drug_general" data-topicid="10108" href="/d/drug information/10108.html" rel="external">tadalafil</a>). Nitrates may induce severe hypotension. (See  <a class="medical medical_review" href="/d/html/1541.html" rel="external">"Sexual activity in patients with cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertrophic cardiomyopathy. Nitrates can induce or increase outflow tract obstruction, even in those not known to have a resting gradient. (See  <a class="medical medical_review" href="/d/html/4950.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction"</a> and  <a class="medical medical_review" href="/d/html/4950.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction", section on 'Chest discomfort'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe aortic stenosis. A sudden decrease in blood pressure can lead to cardiovascular collapse.</p><p></p><p>In view of their lack of survival benefits, nitrates should not be used in preference to beta blockers for the management of chronic, refractory chest pain [<a href="#rid2">2</a>]. In addition, the chronic administration of <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> should not preclude therapy with beta blockers and angiotensin converting enzyme inhibitors. The latter drugs improve survival, a benefit not seen with nitroglycerin. (See <a class="local">'GISSI-3 trial'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">SUBLINGUAL NITROGLYCERIN</span><span class="headingEndMark"> — </span>Sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> is the therapy of choice for acute anginal episodes and for prophylaxis of activities known to elicit angina. It is administered to the patient with acute MI to improve symptoms, lower blood pressure, improve pulmonary congestion, and, in some cases, to help in the diagnosis of coronary artery spasm. (See  <a class="medical medical_review" href="/d/html/1481.html" rel="external">"Vasospastic angina", section on 'Initial therapy'</a>.)</p><p>For the patient presenting to the emergency department with chest pain that may be due to cardiac ischemia, sublingual <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> is commonly administered at a dose of 0.4 mg every five minutes for a total of three doses. Up to 0.6 mg as a single dose may be given to patients with refractory angina, particularly those with hypertension. After the administration of sublingual nitroglycerin, assessment should be made about the need for intravenous nitroglycerin.</p><p class="headingAnchor" id="H4"><span class="h1">INTRAVENOUS NITROGLYCERIN</span><span class="headingEndMark"> — </span>Intravenous <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> is typically initiated in patients with persistent ischemic chest pain despite three sublingual nitroglycerin tablets and other adjunctive therapies.</p><p class="headingAnchor" id="H3943393894"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>An intravenous infusion permits titration of therapy according to the blood pressure response.</p><p class="bulletIndent1"><span class="glyph">●</span>The goal of intravenous <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> therapy is relief of symptoms or a mean arterial blood pressure 10 percent below baseline in normotensive patients and up to 25 to 30 percent in hypertensive patients. The blood pressure lowering should be gradual with careful attention to signs or symptoms of hypoperfusion. The systolic pressure should not fall below 90 mmHg or by more than 30 mmHg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The initial infusion rate is 5 to 10 mcg/min.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the above goals are not met, the infusion rate is gradually increased at approximately 10-minute intervals by 5 to as much as 20 mcg/min.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, the dose should not exceed 400 mcg/min.</p><p></p><p>The infusion is indicated for the first 48 hours for persistent ischemia, heart failure, or hypertension. Intravenous, oral, or topical nitrates can be given after 48 hours for recurrent or persistent indications. At any time, the administration of <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> should not preclude therapy with beta blockers and angiotensin converting enzyme inhibitors.</p><p class="headingAnchor" id="H5"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Despite extensive clinical use, there is remarkably little objective information documenting the effectiveness of intravenous <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> in unstable angina. Several small trials have evaluated the ability of an open-label infusion of nitroglycerin to reduce the frequency of ischemic chest pain; symptomatic relief was noted in each of the reports [<a href="#rid3">3,4</a>]. One randomized trial of 167 patients found that, compared to placebo, intravenous nitroglycerin reduced the frequency and duration of ischemic episodes [<a href="#rid5">5</a>]. In addition, a single randomized trial compared the intravenous, oral, and transdermal nitroglycerin preparations [<a href="#rid6">6</a>]. There was no difference in response among the preparations with regard to symptomatic improvement. However, the small size of this study (40 patients) makes it difficult to draw definitive conclusions.</p><p class="headingAnchor" id="H6"><span class="h3">GISSI-3 trial</span><span class="headingEndMark"> — </span>In the third Gruppo Italiano per lo Studio dell Sopravvivenza nell'Infarto Miocardico (GISSI-3), 19,394 patients with acute MI between 1991 and 1993 were randomly assigned in a two-by-two factorial design to intravenous <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> followed by a nitrate patch or placebo, as well as to <a class="drug drug_general" data-topicid="9565" href="/d/drug information/9565.html" rel="external">lisinopril</a> or placebo [<a href="#rid7">7</a>]. Intravenous nitroglycerin was infused within the first 24 hours, starting at 5 mcg/min and increasing until the systolic blood pressure fell by 10 percent, avoiding systolic pressure below 90 mmHg. Nitrate patch and lisinopril were maintained for six weeks and the patients were followed for six months from the date of randomization.</p><p>The results were analyzed by intention to treat; however, 57 percent of the placebo group received short-term nitrate therapy for angina or heart failure and approximately 11 percent received long-term nitrate therapy. Most of the patients were treated with other appropriate therapies for MI at the time of the trial such as thrombolysis (72 percent), <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (84 percent), and beta blockers (31 percent).</p><p>The primary study end point of mortality at six weeks demonstrated <strong>no significant benefit</strong> of nitrate therapy. However, the subset of patients receiving <a class="drug drug_general" data-topicid="9565" href="/d/drug information/9565.html" rel="external">lisinopril</a> and nitrates had the lowest mortality in the trial (odds ratio 0.83 versus 0.88 for lisinopril alone), suggesting a possible additive beneficial effect of <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> to lisinopril. (See  <a class="medical medical_review" href="/d/html/71.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials"</a>.)</p><p>The nitrate patch was discontinued at six weeks. Six month follow-up continued to show no difference in mortality (18.4 versus 18.9 percent) or left ventricular dysfunction in the patients who received nitrate therapy [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Nitrate tolerance</span><span class="headingEndMark"> — </span>The major concern with a continuous infusion of <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> is the development of nitrate tolerance that occurs in most patients within 24 hours. In GISSI-3, for example, the blood pressure lowering effect of intravenous nitroglycerin was lost within 24 hours [<a href="#rid7">7</a>]. However, prolonged nitroglycerin infusions are not generally needed in acute coronary syndromes, since patients with ST elevation are either rapidly given fibrinolytic therapy or taken directly to the catheterization laboratory, while many patients with non-ST elevation acute coronary syndromes go to the catheterization laboratory within the first 48 hours. (See  <a class="medical medical_review" href="/d/html/1549.html" rel="external">"Nitrates in the management of chronic coronary syndrome", section on 'Nitrate tolerance'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">ORAL AND TRANSDERMAL NITRATES</span><span class="headingEndMark"> — </span>Oral and transdermal nitrates have a limited role in an acute coronary syndrome. Outpatient oral nitrates may be appropriate in the minority of patients who do not attain complete relief of angina after revascularization. (See  <a class="medical medical_review" href="/d/html/1549.html" rel="external">"Nitrates in the management of chronic coronary syndrome", section on 'Commonly used nitrate preparations'</a>.)</p><p>As with intravenous <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a>, there is no evidence that oral nitrate therapy after acute coronary syndrome reduces mortality. This issue was evaluated in the ISIS-4 trial [<a href="#rid9">9</a>]. Longer-term nitrate therapy may help to prevent left ventricular remodeling, but angiotensin converting enzyme (ACE) inhibitors are likely to be more effective for this purpose.</p><p class="headingAnchor" id="H11"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>Nitrates used for this purpose include <a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">isosorbide dinitrate</a> (starting at 10 mg three times daily and increasing to 40 mg three times daily as necessary, given at 8 AM, 1 PM, and 6 PM), <a class="drug drug_general" data-topicid="8581" href="/d/drug information/8581.html" rel="external">isosorbide mononitrate</a> (starting at 30 mg/day in the morning and increasing to 120 mg/day as necessary), or a transdermal <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">Nitroglycerin</a> patch (starting at 0.2 mg/hr and increasing to 0.6 mg/hr with removal of the patch at 6 to 8 PM). These regimens provide an adequate nitrate-free interval to prevent complete nitrate tolerance. (See  <a class="medical medical_review" href="/d/html/1549.html" rel="external">"Nitrates in the management of chronic coronary syndrome", section on 'Nitrate tolerance'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Long-term therapy</span><span class="headingEndMark"> — </span>Long-term nitrate therapy is associated with a modest hemodynamic benefit in patients with a low left ventricular ejection fraction [<a href="#rid10">10</a>]. However, in the era of ACE inhibitors and angiotensin II receptor blockers, nitrate therapy for this purpose would be considered only in patients unable to take an angiotensin inhibitor. (See  <a class="medical medical_review" href="/d/html/71.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials"</a> and  <a class="medical medical_review" href="/d/html/74.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use"</a>.)</p><p class="headingAnchor" id="H492848910"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Nitrate therapy has an important role in the management of patients with an acute coronary syndrome, despite the absence of a mortality benefit. It can be of value in reducing or potentially eliminating pain (either initial or recurrent) due to myocardial ischemia, improving symptoms of pulmonary congestion, lowering blood pressure in hypertensive patients, and aiding in the diagnosis and management of the rare patient who presents with variant angina (coronary artery spasm).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nitrates are part of combined modality therapy for symptoms or signs of myocardial ischemia, heart failure, and hypertension in the patient with an acute coronary syndrome. (See  <a class="medical medical_review" href="/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are several important adverse effects of nitrate therapy. Avoid nitrates in patients with systolic blood pressure &lt;90 mmHg or ≥30 mmHg below baseline, marked bradycardia or tachycardia, known or suspected right ventricular infarction, phosphodiesterase inhibitor use within the last 24 to 48 hours, hypertrophic cardiomyopathy, or severe aortic stenosis. (See <a class="local">'Side effects and caution'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The development of hypotension in patients with volume depletion, right ventricular infarction, or recent use of a phosphodiesterase inhibitor for erectile dysfunction (eg, <a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">sildenafil</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The prevention of optimal dosing of beta blockers or <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> sulfate due to its blood pressure lowering effect.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Garadah T, Ghaisas NK, Mehana N, et al. Impact of intravenous nitroglycerin on pulsed Doppler indexes of left ventricular filling in acute anterior myocardial infarction. Am Heart J 1998; 136:812.</a></li><li class="breakAll">Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).</li><li><a class="nounderline abstract_t">DePace NL, Herling IM, Kotler MN, et al. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action. Arch Intern Med 1982; 142:1806.</a></li><li><a class="nounderline abstract_t">Kaplan K, Davison R, Parker M, et al. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy. Am J Cardiol 1983; 51:694.</a></li><li><a class="nounderline abstract_t">Karlberg KE, Saldeen T, Wallin R, et al. Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: a double-blind placebo-controlled study. J Intern Med 1998; 243:25.</a></li><li><a class="nounderline abstract_t">Curfman GD, Heinsimer JA, Lozner EC, Fung HL. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective, randomized trial. Circulation 1983; 67:276.</a></li><li><a class="nounderline abstract_t">GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343:1115.</a></li><li><a class="nounderline abstract_t">Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. J Am Coll Cardiol 1996; 27:337.</a></li><li><a class="nounderline abstract_t">ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669.</a></li><li><a class="nounderline abstract_t">Mahmarian JJ, Moyé LA, Chinoy DA, et al. Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial. Circulation 1998; 97:2017.</a></li></ol></div><div id="topicVersionRevision">Topic 64 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9812075" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Impact of intravenous nitroglycerin on pulsed Doppler indexes of left ventricular filling in acute anterior myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9812075" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of intravenous nitroglycerin on pulsed Doppler indexes of left ventricular filling in acute anterior myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6812520" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6402912" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9487328" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: a double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6401229" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910229" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8557903" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7661937" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9610531" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
